MultiStem
- Generic Name
- MultiStem
- Drug Type
- Biotech
- Unique Ingredient Identifier
- WNR9FH307P
Overview
MultiStem is an intravenously-administered, off-the-shelf proprietary product developed which comprises Multipotent Adult Progenitor Cells (MAPCs). Like mesenchymal stem cells, MAPCs are derived from bone-marrow stroma and are non-hematopoietically adherent. They have immunomodulatory and pro-angiogenic properties while also being mostly non-immunogenic. Additional benefits of MultiStem include their low immunogenicity, meaning they can be administered without tissue matching or concurrent immunosuppressive agents. The cells for creation of the product are isolated from a qualified donor and expanded on a large scale and then frozen until use. After administration, the cells are cleared from the body over time. Currently, MultiStem is being investigated against neurological, inflammatory, immune, and cardiovascular diseases and conditions.
Background
MultiStem is an intravenously-administered, off-the-shelf proprietary product developed which comprises Multipotent Adult Progenitor Cells (MAPCs). Like mesenchymal stem cells, MAPCs are derived from bone-marrow stroma and are non-hematopoietically adherent. They have immunomodulatory and pro-angiogenic properties while also being mostly non-immunogenic. Additional benefits of MultiStem include their low immunogenicity, meaning they can be administered without tissue matching or concurrent immunosuppressive agents. The cells for creation of the product are isolated from a qualified donor and expanded on a large scale and then frozen until use. After administration, the cells are cleared from the body over time. Currently, MultiStem is being investigated against neurological, inflammatory, immune, and cardiovascular diseases and conditions.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2013/04/26 | Phase 1 | Terminated | Prof. Dr. Marc-H. Dahlke, Ph. D. | ||
2010/11/15 | Phase 2 | Completed |
FDA Approved Products
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|
No FDA products found
No FDA products found for this drug
EMA Approved Products
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|
No EMA products found
No EMA products found for this drug
Singapore Approved Products
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. | Online |
|---|
No Singapore products found
No Singapore products found for this drug
China Approved Products
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|
No China products found
No China products found for this drug
Australia Approved Products
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
|---|
No Australia products found
No Australia products found for this drug